Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P < 0.001) and was further reduced when effective therapies were combined (P < 5 × 10(-6)), with no change in drug-resistant organoids. Drug response in xenograft-derived organoids was validated with tumor growth measurements in vivo and staining for proliferation and apoptosis. Heterogeneous cellular responses to drug treatment were also resolved in organoids. Optical metabolic imaging shows potential as a high-throughput screen to test the efficacy of a panel of drugs to select optimal drug combinations. Cancer Res; 74(18); 5184-94. ©2014 AACR.

[1]  C. Bondy,et al.  Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Carlos L Arteaga,et al.  Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.

[3]  Alex J. Walsh,et al.  Ex vivo optical metabolic measurements from cultured tissue reflect in vivo tissue status , 2012, Journal of biomedical optics.

[4]  Paolo P. Provenzano,et al.  Fluorescence Lifetime Imaging of Endogenous Fluorophores in Histopathology Sections Reveals Differences Between Normal and Tumor Epithelium in Carcinoma In Situ of the Breast , 2009, Cell Biochemistry and Biophysics.

[5]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  N. Ramanujam,et al.  In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia , 2007, Proceedings of the National Academy of Sciences.

[7]  C. Hudis,et al.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Lakowicz,et al.  Fluorescence lifetime imaging of free and protein-bound NADH. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Pestell,et al.  Breast cancer stem cells. , 2012, The international journal of biochemistry & cell biology.

[11]  Melissa C. Skala,et al.  Optical metabolic imaging of live tissue cultures , 2013, Photonics West - Biomedical Optics.

[12]  S. Hilsenbeck,et al.  Neoadjuvant trastuzumab induces apoptosis in primary breast cancers , 2005, Nature Clinical Practice Oncology.

[13]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[14]  N. Ramanujam,et al.  Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. , 2005, Cancer research.

[15]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[16]  Melissa C. Skala,et al.  An automated image processing routine for segmentation of cell cytoplasms in high-resolution autofluorescence images , 2014, Photonics West - Biomedical Optics.

[17]  Alex J Walsh,et al.  Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. , 2013, Cancer research.

[18]  Jenny C. Chang,et al.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. , 2013, Cancer research.

[19]  H. Akaike.  A new look at the statistical model identification , 1974 .

[20]  Kevin W. Eliceiri,et al.  Multiphoton microscopy and fluorescence lifetime imaging microscopy (FLIM) to monitor metastasis and the tumor microenvironment , 2008, Clinical & Experimental Metastasis.

[21]  R. Mancini,et al.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics , 2012, Oncotarget.

[22]  B. Chance,et al.  Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. , 1979, The Journal of biological chemistry.

[23]  V. Seewaldt,et al.  Tumor and Stem Cell Biology Cancer Research Optical Redox Ratio Differentiates Breast Cancer Cell Lines Based on Estrogen Receptor Status , 2010 .

[24]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .

[25]  Jordi Rodon,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[26]  Jens Eickhoff,et al.  In vivo multiphoton fluorescence lifetime imaging of protein-bound and free nicotinamide adenine dinucleotide in normal and precancerous epithelia. , 2007, Journal of biomedical optics.

[27]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[28]  K. Yoshihara,et al.  Picosecond fluorescence lifetime of the coenzyme of D-amino acid oxidase. , 1980, The Journal of biological chemistry.

[29]  Young L. Kim,et al.  Endogenous optical biomarkers of normal and human papillomavirus immortalized epithelial cells , 2008, International journal of cancer.

[30]  H. Mukai,et al.  Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. , 2006, Japanese journal of clinical oncology.

[31]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[32]  T. Powles,et al.  Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Mancini,et al.  Novel anti‐ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors , 2012, Journal of cellular physiology.

[34]  J. P. Kennedy,et al.  Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells , 2009, Clinical Cancer Research.

[35]  D. Mankoff,et al.  PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake , 2011, Clinical Cancer Research.

[36]  Patricia J. Keely,et al.  Use of three-dimensional collagen gels to study mechanotransduction in T47D breast epithelial cells , 2005, Biological Procedures Online.

[37]  Melissa C. Skala,et al.  Optical imaging of metabolism in HER2 overexpressing breast cancer cells , 2011, Biomedical optics express.

[38]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[39]  A. J. Bain,et al.  Separating NADH and NADPH fluorescence in live cells and tissues using FLIM , 2014, Nature Communications.

[40]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[41]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[42]  Ruth E. Cameron,et al.  A Multifunctional 3D Co-Culture System for Studies of Mammary Tissue Morphogenesis and Stem Cell Biology , 2011, PloS one.

[43]  References , 1971 .

[44]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[45]  Daohai Zhang,et al.  Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer* , 2005, Molecular & Cellular Proteomics.